Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioLineRx Ltd. Regulatory Filings 2015

Nov 16, 2015

6692_ffr_2015-11-16_e2b84eba-b4d6-4725-b5d1-0691ad66ab03.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

6-K 1 zk1517595.htm 6-K zk1517595.htm Licensed to: ZKG Document Created using EDGARizer 2020 5.5.2.0 Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2015


BioLineRx Ltd.

(Translation of Registrant’s name into English)


P.O. Box 45158

19 Hartum Street

Jerusalem 91450, Israel

(Address of Principal Executive Offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F o

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes o No x

On November 16, 2015, the Registrant will issue a press release announcing its financial results for the three and nine months ended September 30, 2015. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of September 30, 2015, and for the three and nine months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated November 16, 2015;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of September 30, 2015, and for the three and nine months and then ended;

Exhibit 3 - Registrant’s operating and financial review as of Septmeber 30, 2015, and for the three and nine months then ended.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By: /s/ Philip Serlin
Philip Serlin
Chief Financial and Operating Officer

Dated: November 16, 2015